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Abstract 
Background&Aims: The higher prevalence of obesity is associated 
with a number of cardiovascular risk factors. The purpose of this study is to 
asses the prevalence of obesity in adult patients with diabetes mellitus (DM) 
type 2 and autoimmune chronic thyroiditis (ACT). Methods: The studied 
group was represented by 78 adult patients with DM type 2 and ACT (70 
women and 8 men). Were used clinical, biochemical and imaging 
parameters. Results: 53 (67.94%) (45 women and 8 men) had different types 
of obesity. The obesity was more frequent in men than in women (100% vs. 
64.28%, p = 0.04, X2 = 4.2). In function of obesity type, android obesity was 
prevailed (94.34 % of cases), following by gynoid obesity type (5.66 %). 
Also, 26.92 % were overweight (all women). Regarding the type of android 
obesity, 39.62 % had type I, 37.73 % type II and 22.64 % type III. Also, 
64.15 % had hypertension and dyslipidemia 79.24 %. Conclusions: In 
patients with DM type 2 and ACT the obesity prevailed in men. It was 
android type, represented an increased risk of cardiovascular morbidity-
mortality, particularly for atherosclerotic cardiovascular disease. The 
association of thyroid disease, which over time can evolve with 
hypothyroidism, is an additional risk factor for atherosclerotic cardiovascular 
disease.  
 
Keywords: Prevalence, obesity, adults, autoimmune chronic thyroiditis, 
diabetes mellitus type 2  
 
Introduction 
Obesity is a disease characterized by weight gain due to the body fat 
and currently defined by a body mass index value (BMI) ≥ 30 kg/m2. 
Obesity is a major public health problem in both developed countries 
and the developing ones, with a higher frequency, reaching affect all age 
groups and all social categories. In recent decades, obesity has reached 
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epidemic proportions, becoming the major cause of morbidity and premature 
mortality worldwide. According to WHO, worldwide, approximately 1 
billion adults are overweight and over 300 million are obese (Şerban et al, 
1999). 
Significant progress in the epidemiology of adult obesity was its 
standardization by the WHO in 1988. According to this classification, are 
considered obese the people with BMI ≥ 30 kg/m2 and those with BMI 
between 25 and 30 kg/m2, overweight (Şerban et al, 1999). 
In most EU countries, the number of new cases of obesity has 
increased rapidly in recent decades, more pronounced in males. In Central 
and Eastern Europe (Russia, Czech Republic, countries of the Former 
Yugoslavia) it was observed a much higher frequency in women than in men 
(Şerban et al, 1999). 
Age is the most important factor influencing the prevalence of 
obesity. Its frequency increases parallel with age, at least up to 50-60 years 
and over 70 years it is recording a decrease, in both men and women (Şerban 
et al, 1999). 
In developing countries, the peak prevalence is recorded at 0-45 
years, while in economically developed countries; it is recorded usually after 
the age of 60 years (Şerban et al, 1999). 
Regarding gender, there is a tendency of higher rates of obesity in 
women (with obvious differences in Arab countries, African continent, South 
America, Mexico and Central Europe), but also in other countries such as 
Malta, Cyprus, Greece, Austria, Ireland, its frequency is higher in men 
(Şerban et al, 1999). 
Overweight is generally more common in men (Şerban et al, 1999). 
WHO recognizes obesity as a disease of epidemic proportions in 
many countries. Its prevalence is increasing. Obesity has also become a 
problem in children and teenagers, recent data suggest that 8% are obese 
(Bundred et al, 2001). It seems that it occurs as a consequence of the 
decrease in daily physical activity and increased caloric intake, especially 
intake of fast food products. 
WHO MONICA study conducted in Europe in 39 countries on 
subjects aged 35-64 years reported a prevalence of obesity of 10-20% for 
men and 15-20% for women. Overweight were more common among men, 
obesity and overweight frequency was over 50% in Europe (Uwaifo et al, 
2002). 
In our country, the prevalence of obesity is 17% in rural and 20% in 
urban, being more common in women; in children ranges between 5-10% 
(Pencea et al, 2004). 
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Urziceni study showed that at adult population overweight met in 
22.8% of cases, and obesity in 25.2%, totaling 48% of cases (Pencea et al, 
2004). 
The increased prevalence of obesity is found in USA: 67% of men 
are obese and 27.5% overweight, while 62% of women are obese and 27.5% 
overweight (Pencea et al, 2004). 
Obesity is also responsible for the increase of type 2 diabetes, 90% of 
patients with type 2 diabetes are obese. The risk of developing diabetes 
increases with increasing BMI (risk is 40-80 times higher at a BMI > 40 
kg/m2 than to a BMI < 21 kg/m2). Furthermore, overweight (BMI > 25 
kg/m2) occurs in 64% of cases in men and in 74% of cases in women 
(Wilding, 2003). 
Although obesity is a risk factor for developing diabetes, only 50% of 
obese develop diabetes (Wilding, 2003). 
In the case of thyroid disease, obesity is secondary to those who 
evolve with hypothyroidism due to the decrease of the basal metabolic rate. 
Hashimoto thyroiditis is a chronic autoimmune disease which in time 
can evolve with hypothyroidism. Weight gain due to the hypothyroidism is 
around 10% by weight from euthyroid stage and it is attributed to 
accumulation of the fluid in the interstitial tissue. 
Obesity is associated with an increased risk of diabetes, dyslipidemia, 
kidney disease, cardiovascular disease, all-cause mortality, and cancer 
(Golden et al, 2009). Thus, severe obesity is an important cause of premature 
mortality among middle-aged adults (Mehta et al, 2009). Moreover, obesity, 
especially central obesity, is linked to many endocrine abnormalities 
(Kokkoris et al, 2003), including thyroid dysfunction (Reinehr, 2010). This is 
not surprising because T3 regulates energy metabolism and thermogenesis 
and plays a critical role in glucose and lipid metabolism, food intake, and the 
oxidation of fatty acids (Reinehr, 2010). 
 
Material And Method 
Method 
 
Investigated Population 
78 patients with DM type 2 (70 F and 8 M), aged between 18 and 79 
years represented the studied group. 
 
Methods Of Investigation  
The methods of investigation were represented by clinical data - case 
history, current status, anthropometric measurements: waist circumference 
and body mass index (BMI), determination of systolic and diastolic blood 
pressure, imagistic- thyroid ultrasound, biochemical - for glycemic 
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balance: fasting blood glucose, glycosylated hemoglobin, for lipid 
metabolism: total cholesterol, triglycerides, HDL cholesterol, LDL 
cholesterol, investigation of the thyroid gland: TSH, FT4, FT3, thyroid 
antibodies.  
 
Investigation of glycemic balance  
Determination of plasma glucose was performed by enzyme 
technique with glucosooxidasis. Normal values were taken between 70 - 110 
mg%; diabetes mellitus - values equal or over 126 mg%, impaired glucose 
tolerance - values between 110 - 125 mg% and the OGTT at 2 h between 140 
- 200 mg% and impaired fasting glucose - values between 110 - 125 mg% 
and OGTT at 2 h under 140 mg%.  
Determination of HbA1c was achieved through the DiaStat for 
measuring HbA1c reported to the total HbA.  
 
Investigation of lipid metabolism  
The "fasting" lipid profile in the peripheral blood was appreciated 
by determining the total cholesterol (TC), triglyceride (TG), HDL-
cholesterol (HDL-C), LDL-cholesterol (LDL-C) and the ratio TC / HDL-C. 
We used laboratory methods based on the enzyme principle, both for TC 
(Dimension AR, Dade Behring Inc., USA) and TG and HDL-C (REflectron 
IV, Roche, Switzerland). The level of LDL-C was calculated according to 
the Friedwald's formula: LDL = TC - (HDL + TG / 5). Were considered 
normal: TC < 200 mg%, TG < 150 mg%, HDL-C > 45 mg%, LDL-C < 115 
mg%, TC / HDL-C between 2-3.5.  
 
Investigation of the thyroid gland  
To determine the TSH level in plasma, the free fraction of 
triiodotironin (FT3), and the plasma free fraction of thyroxin (FT4) were 
performed a quantitative method ARCHITECT; witch is an immunological 
method, Chemilumnescent Microparticle Immunoassay (CMIA). Normal 
values were following: TSH = 0.465-4.68 Miu/ml, FT3 = 3.69 -10.4 pmol/l, 
FT4 = 10-28.2 pmol/l.  
The immunological parameters were represented by autoimmune 
thyroid markers - antibodies (antiTPO and antiTg antibodies).  
To determine serum levels of antiTPO antibodies it was used the kit 
AxSYM antiTPO, an immunological method (Microparticle Enzyme 
Immunoassay) (MEIA). Normal values:  antiTPO antibodies <35 IU/ml.  
To determine serum levels of antiTg antibodies it was used the kit 
AxSYM antiTg, a MEIA method as well (Microparticle Enzyme 
Immunoassay). Normal values: antiTg antibodies <55 IU/ml.  
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Thyroid ultrasound was performed in all cases and allowed us to 
measure thyroid volume, thyroid study and the changes in parenchyma’s 
density.  
An increased density, uniform, characterizes normal thyroid parenchyma 
easily distinguished from the neck muscles that are hypo dens.  
Inflammatory processes and autoimmune pathology appears hypo 
dens.  The scale was assessed as being discreet +, moderate ++ and marked 
+++.  
In the autoimmune thyroid disease the parenchyma of the gland 
appears hypo dens.  
Chronic autoimmune thyroid disorder appears with a hypoecogenity 
of the parenchyma and normal or increased thyroid volume.  
 
Determination of blood pressure (BP) 
Blood pressure was measured using conventional 
sphygmomanometers (Didytest, Germany), respecting following conditions: 
"fasting", subject seated with left arm raised to the heart, physical rest for at 
least 5-10 min without the subjects smoke or drink coffee before the 
determination. The studied values were arithmetic mean of BP values 
obtained by three successive determinations. 
Determination of body mass index (BMI) and waist 
circumference (WC) 
We determined the subjects body weight (kg) and height (m) and we 
calculate BMI according to the formula: BMI (kg/m2) = body weight/height2. 
The results were interpreted as follows: normal (18.5 to 24.9 kg/m2), 
overweight (25 to 29.9 kg/m2), obesity type I (30 to 34.9 kg/m2), obesity type 
II (35 to 39.9 kg/m2), obesity type III (> 40 kg/m2), underweight (<18.5 
kg/m2) (De Backer, 2003, MacLean, 2000). 
Waist circumference was determined with a centimeter by measuring 
the waist at the half distance between the umbilicus and xiphoid appendix 
(Şerban et al, 1999). 
 
Statistical Analysis 
For statistical analysis we used Microsoft Excel and POP Tools from 
Microsoft Office 2003 and EPI 2000 program. To measure the quantitative 
variables were determined average (A) and standard deviation (SD), and to 
assess the gender differences we used the unpaired t test and ANOVA test, 
considering statistically significant a p < 0.05. 
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Results And Discussion 
From a group of 78 patients with DM type 2 and ACT (70 women 
and 8 men), 53 (67.94%) (45 women and 8 men) had different types of 
obesity. The medium age was 54.45 ± 9.57 years.  
The obesity was more frequent in men than in women (100% vs. 
64.28%, p = 0.04, X2 = 4.2). In function of obesity type, android obesity was 
prevailed (94.34 % of cases), following by gynoid obesity type (5.66 %). 
Also, 26.92 % were overweight (all women). 
Fig. 1. Prevalence of obesity by gender at patients with DM type 2 and ACT 
Fig. 2. Prevalence of obesity type at patients with DM type 2 and ACT 
 
Thyroid dysfunction is associated with changes in body weight and 
composition, body temperature, and total and resting energy expenditure 
independently of physical activity. Moreover, weight gain often develops 
after treatment of thyroid dysfunction (Kaptein et al, 2009). Both subclinical 
and overt hypothyroidism is frequently associated with weight gain, 
decreased thermogenesis, and metabolic rate (Hoogwerf et al, 1984, Asvold 
et al, 2009). In a recent cross-sectional, population-based study of 27,097 
individuals above 40 yr of age with body mass index (BMI) of at least 30.0 
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kg/m2, subclinical and overt hypothyroidism correlated with a higher BMI 
and a higher prevalence of obesity in both smokers and nonsmokers (Asvold 
et al, 2009). It has been noted that small variations in serum TSH caused by 
minimal changes in l-T4 dosage during replacement therapy are associated 
with significantly altered resting energy expenditure in hypothyroid patients 
(Al-Adsani et al, 1997). These studies support the clinical evidence that mild 
thyroid dysfunction is linked to significant changes in body weight and likely 
represents a risk factor for overweight and obesity. 
The role of obesity as a risk factor for type 2 diabetes has been 
demonstrated by numerous prospective studies that included Caucasian 
populations in Norway, Sweden, Israel and the U.S., Mexicans from Texas, 
USA, and Pima Indians (Pencea et al, 2004). 
In other 2 population-based studies conducted in Israel and in the 
Pima Indians, it was found that the duration and types of obesity are risk 
factors for type 2 diabetes. In the group of Pima Indians, the risk of type 2 
diabetes is twice at people with 10 years obesity history or over this period 
compared with those with a less than 5 years obesity history (Pencea et al, 
2004). 
Central distribution of body adiposity is a major risk factor for type 2 
diabetes, independent of the type of obesity, hypothesis demonstrated by the 
prospective studies conducted on populations from Sweden, Japan and Pima 
Indians. 
In the group of Pima Indians, 5-year longitudinal studies have shown 
the association of impaired glucose tolerance with weight gain, decreased 
insulin secretion and action. No changes were observed in hepatic glucose 
production. The higher weight and the defect of synthesis / action of insulin, 
and increased hepatic glucose production characterize abnormal glucose 
tolerance progression to diabetes (Pencea et al, 2004). 
Obesity, especially abdominal (android type), with hip/waist ratio 
increased, contributing to the occurrence of hyperglycemia, probably by 
reducing the number of insulin receptors (Wilding, 2003). 
Epidemiological studies show that over 80% of patients with type 2 
diabetes are or were obese and 40% from obese are diabetics, if they are 
active detected (OGTT) (Katsilambros, 2000, Katsilambros et al, 2003). 
Regarding the types of android obesity, 39.62 % had type I, 37.73 % 
type II and 22.64 % type III.  
Table 1. Prevalence of obesity type by gender at patients with DM type 2 and ACT 
Obesity type F M p 
I 17 4 < 0.001, X2 = 24.9 
II 16 4 0.00014, X2 = 14.4 
III 12 0 < 0.001, X2 = 24 
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Fig.3. Prevalence of obesity type at patients with DM type 2 and ACT 
 
In function of TSH level, 62.26% were euthyroid, and 38.74% 
hypothyroid (p = 0.01, X2 = 6.38). 
TSH seems to be positively related to the type of obesity (Iacobellis, 
2005). Thyroid hormone levels have been reported to be normal, increased, 
and decreased in obese patients (Iacobellis, 2005); this discrepancy among 
studies probably reflects the fact that patients were examined at different 
times (during overeating or a hypocaloric diet) and may differ in type of 
obesity and in plasma insulin sensitivity. 
There is some debate about the link between obesity and the risk of 
autoimmune thyroid dysfunction (AITD), which is the main cause of 
hypothyroidism in adults. The prevalence of AITD in obesity has been 
reported to be 12.4% in children and between 10 and 60% in adults 
(Marzullo et al, 2010, Rotondi et al, 2009). This discrepancy may be due to 
such factors as sex, age, menopausal status, smoking habit, environmental 
factors, iodine intake, and type of obesity. 
Also, 64.15 % had hypertension and dyslipidemia 79.24 %. In 
function of dyslipidemia type, predominate mixed dyslipidemia (64.15%), 
followed by hypercholesterolemia (28.57%) and hypertryglyceridemia 
(9.52%).  
 
Fig.4. Prevalence of other cardiovascular risk factors at obese patients with DM type 2 and ACT 
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Marzullo et al. in their study show that 69% of their patients had 
severe obesity (BMI > 40 kg/m2), and the prevalence of hypothyroidism was 
higher in obese patients than in a control group of age- and sex-matched 
subjects with normal BMI (p < 0.05), as documented by lower FT3 and FT4 
plasma levels (p < 0.01) and a deranged lipid profile. 
The onset of thyroid hormone deficiency, especially the subclinical 
form, may go undiagnosed in obese patients. Consequently, these patients 
will continue to increase in weight and will develop a deranged lipid profile, 
thereby bringing the thyroid/obesity association to a full circle. 
Recent studies suggest that a higher BMI is associated with an 
increased risk of thyroid cancer (Paes et al, 2010). Moreover, a serum TSH 
in the upper half of the normal range is considered as an independent 
predictor for the presence of thyroid cancer in thyroid nodules (Boelaert, 
2006, Fiore et al, 2009). Both of these findings together suggest that the 
higher serum TSH levels could be responsible for the development of thyroid 
malignancy in obese patients. 
Obesity and thyroid dysfunction are common diseases, and 
consequently clinicians should be particularly alert to the possibility of 
thyroid dysfunction in obese patients. On the other hand, although thyroid 
hormones have been inappropriately and frequently used in attempts to 
induce weight loss in obese euthyroid subjects, there is no indication for their 
administration to control body weight except in obese hypothyroid subjects. 
In fact, long-term treatment with thyroid hormones does not significantly 
improve weight loss in obese subjects without thyroid dysfunction and, on 
the contrary, will entail a risk of adverse effects (Kaptein et al, 2009). It is 
conceivable that selected thyroid analogs might be a means by which to 
improve weight loss by increasing energy expenditure (as well as improving 
lipid profiles) in obese patients with low T3 during continued caloric 
deprivation (Ladenson et al, 2010). 
 
Conclusion 
In patients with DM type 2 and ACT the obesity prevailed in men. It 
was android type, represented an increased risk of cardiovascular morbidity-
mortality, particularly for atherosclerotic cardiovascular disease.  
Regarding the type of android obesity, prevailed type I, followed by 
type II and III.  
Were also associated another cardiovascular risk factors such as 
hypertension and dyslipidemia. Regarding dyslipidemia type, prevailed 
mixed dyslipidemia, followed by hypercholesterolemia and 
hypertryglyceridemia.  
Most of the patients were euthyroid and the remaining hypothyroid.  
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The association of thyroid disease, which over time can evolve with 
hypothyroidism, is an additional risk factor for atherosclerotic cardiovascular 
disease.  
It is disputable to administrate thyroid hormones at obese patients 
with normal thyroid function because they don’t improve weight, but 
increase the risk of adverse effects. Some thyroid analogs can be 
administrating to these patients because they improve lipid profile and 
determinate weight loss.  
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